Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.

DiNicolantonio, James J; Barroso-Aranda, Jorge; McCarty, Mark F

DiNicolantonio, James J; Barroso-Aranda, Jorge; McCarty, Mark F.

DiNicolantonio JJ; Department of Preventive Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA jjdinicol@gmail.com.
Barroso-Aranda J; Clinica Libre de Adicciones, Tijuana, Mexico.
McCarty MF; Catalytic Longevity, Encinitas, California, USA.

Open Heart ; 8(1)2021 04.

Article in English | MEDLINE | ID: covidwho-1194230

Subject(s)

COVID-19; Ivermectin; Anti-Inflammatory Agents/pharmacology; Humans; Ivermectin/pharmacology; Receptors, Glycine; SARS-CoV-2

Keywords

COVID-19; cardiomyopathy; electronic health records; hypertrophic

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / COVID-19 Topics: Long Covid Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Openhrt-2021-001655

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google